Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

96.92EUR
15 Feb 2019
Change (% chg)

€0.32 (+0.33%)
Prev Close
€96.60
Open
€96.54
Day's High
€97.58
Day's Low
€96.10
Volume
385,026
Avg. Vol
579,445
52-wk High
€100.20
52-wk Low
€74.54

Select another date:

Tue, Feb 5 2019

Photo

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

FRANKFURT GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

Merck KGaA wins GSK for immunotherapy deal worth up to $4.2 bln

FRANKFURT, Feb 5 GlaxoSmithKline bolstered its cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy.

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

UPDATE 2-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

CORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug, Bavencio, to treat a form of ovarian cancer in previously untreated patients.

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Dec 21 Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

Palantir to offer cancer analytics under JV deal with Germany's Merck

((This NOV 19 story corrects to show Merck is Palantir's exclusive partner within the JV, not for all of Palantir's healthcare activities, paragraph 11))

CORRECTED-UPDATE 1-Palantir to offer cancer analytics under JV deal with Germany's Merck

FRANKFURT, Nov 19 Palantir Technologies Inc will set up a cancer data analytics joint venture with German lab supplies company Merck KGaA, as the U.S. analytics and security firm makes further inroads into health care.

Palantir to offer cancer analytics under JV deal with Germany's Merck

FRANKFURT, Nov 19 Palantir Technologies Inc will set up an exclusive cancer research joint venture with German lab supplies company Merck KGaA, as the U.S. data analytics and security firm makes further inroads into health care.

Merck KGaA third-quarter earnings down on weak Latam currencies

FRANKFURT German drugs and lab supplies maker Merck KGaA saw adjusted core earnings decline and lowered its full-year profit outlook as a decline in Latin American currencies weighed on the value of overseas sales.

Select another date: